// App-Quantinova.ai

: Nintedanib: A Potent Inhibitor of Invadosome Formation by Lung Fibroblasts Derived from Patients with Idiopathic Pulmonary Fibrosis

Researchers

Presenter

  • M. Lebel

Principal Investigators

  • D. Cliche

  • M. Charbonneau

  • G. Bilodeau

  • A. M. Cantin

  • C. M. Dubois

Medical Centers

  • Universite de Sherbrooke, Sherbrooke, QC, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Pulmonary/Respiratory Diseases

Disease

  • Idiopathic pulmonary fibrosis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

  • Becaplermin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved